Journal article

Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry

William Berry, Benjamin S Daniel, Christopher Baker, Peter Foley

Australasian Journal of Dermatology | WILEY | Published : 2020


Funding Acknowledgements

The Australasian Psoriasis Registry is supported by Epiderm and the Skin Health Institute Inc.. Additional funding has been received from Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer and Sun Pharma. WB, BD and CB have no conflicts of interest relevant to this work to declare. PF has advisory roles with Abbvie, Amgen, Celgene, Janssen, Lilly, Mayne Pharma, Merck, Novartis, Pfizer, Sun Pharma, UCB Pharma, Valeant, Wintermute, Galderma, GSK, Leo Pharma and Sanofi and is an investigator on clinical trials with those companies and Astra Zeneca, Boehringer Ingelheim, BMS, Botanix, Celtaxsys, CSL, Cutanea, Dermira, Genentech, Regeneron Pharmaceuticals Inc, and Roche. However, no funding was received for the preparation of this publication. As such, these are not relevant to this work.